Zimmer Biomet Holdings, Inc. (ZBH) to Issue Quarterly Dividend of $0.24 on January 30th

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) declared a quarterly dividend on Wednesday, December 17th. Investors of record on Tuesday, December 30th will be given a dividend of 0.24 per share by the medical equipment provider on Friday, January 30th. This represents a c) annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, December 30th.

Zimmer Biomet has a dividend payout ratio of 11.5% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Zimmer Biomet to earn $8.87 per share next year, which means the company should continue to be able to cover its $0.96 annual dividend with an expected future payout ratio of 10.8%.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $90.39 on Friday. The company has a market capitalization of $17.91 billion, a P/E ratio of 22.37, a PEG ratio of 2.41 and a beta of 0.61. Zimmer Biomet has a fifty-two week low of $85.33 and a fifty-two week high of $114.44. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.39 and a current ratio of 2.43. The stock has a 50 day moving average price of $95.07 and a two-hundred day moving average price of $96.65.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, topping the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The company had revenue of $2 billion for the quarter, compared to the consensus estimate of $2.01 billion. During the same period in the previous year, the firm earned $1.74 earnings per share. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on ZBH shares. Stifel Nicolaus set a $110.00 price target on Zimmer Biomet in a research note on Wednesday, November 5th. BTIG Research dropped their target price on shares of Zimmer Biomet from $122.00 to $112.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Baird R W lowered shares of Zimmer Biomet from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Citigroup decreased their price target on shares of Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating for the company in a research note on Thursday, December 11th. Finally, Royal Bank Of Canada lowered their price objective on shares of Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $107.50.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.